Skip to main content
AUTOBIO DIAGNOSTICS CO., LTD logo

AUTOBIO DIAGNOSTICS CO., LTD — Investor Relations & Filings

Ticker · 603658 ISIN · CNE100002GC4 LEI · 300300HTZSCUCA32U369 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,290 across all filing types
Latest filing 2021-04-22 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 603658

About AUTOBIO DIAGNOSTICS CO., LTD

https://en.autobio.com.cn/

Autobio Diagnostics Co., Ltd. specializes in the research, development, manufacturing, and distribution of comprehensive in vitro diagnostic (IVD) solutions. The company offers an extensive portfolio of products across multiple clinical disciplines, including immunoassay, microbiology, and molecular diagnostics. Key offerings include high-throughput chemiluminescence immunoassay (CLIA) systems, enzyme-linked immunosorbent assay (ELISA) kits, and automated microbiology platforms for blood culture and microbial identification. Autobio also provides integrated laboratory automation systems designed to enhance diagnostic efficiency and accuracy. By focusing on technological innovation and quality, the company serves clinical laboratories, hospitals, and medical institutions worldwide, supporting the detection of infectious diseases, oncology markers, and various metabolic disorders.

Recent filings

Filing Released Lang Actions
安图生物关于使用闲置募集资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Zhengzhou Antu Biological Engineering Co., Ltd. regarding the use of idle raised funds for cash management. It details the amounts of idle funds from convertible bonds and private stock issuance, the types of financial products for investment, risk control measures, and approvals from the board, supervisory committee, independent directors, and the sponsor institution. The document is a formal disclosure about the company's financing fund management activities, specifically the use of idle raised funds for cash management. It does not contain financial statements, audit opinions, or detailed financial results. It is not a report like an Annual Report or Interim Report, nor is it a call transcript or a voting result. It is a regulatory announcement about capital management activities related to fundraising proceeds. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length is over 5,000 characters and contains substantive information about financing activities, not just a brief notice or certification, so it is not RNS or RPA.
2021-04-22 Chinese
安图生物独立董事关于公司第三届董事会第二十二次会议相关事项的事前认可意见
Board/Management Information Classification · 95% confidence The document is a statement from independent directors regarding their prior approval opinions on matters to be discussed at a board meeting, specifically about the appointment of the 2021 audit firm and a related party loan transaction. It references regulatory guidelines for independent directors and internal company rules. The document is short (564 characters) and does not contain financial statements or detailed financial data. It is not an audit report itself, nor an annual or interim report. It is a board-related announcement concerning management and governance matters. Therefore, it fits best under Board/Management Information (MANG).
2021-04-22 Chinese
安图生物董事会关于会计政策变更的说明
Board/Management Information Classification · 95% confidence The document is a statement from the company's board regarding a change in accounting policy due to the adoption of a new lease accounting standard issued by the Ministry of Finance. It explains the impact of the accounting policy change on financial statements and confirms compliance with accounting standards. There is no financial data or full report included, nor is it an announcement of a meeting or voting results. It is a board-level communication about accounting policy changes, which fits best under Board/Management Information (MANG). The document length is short and focused on management's explanation of accounting policy changes, not a full audit or annual report.
2021-04-22 Chinese
安图生物关于使用闲置自有资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Zhengzhou Antu Biological Engineering Co., Ltd. regarding the use of idle self-owned funds for cash management, including details about entrusted financial management, investment amounts, types, terms, risk control measures, and independent director opinions. It is a disclosure about the company's financing and cash management activities rather than a financial report or earnings release. The document length is about 2594 characters, which is relatively short and focused on a specific financing-related announcement. There is no financial statement or comprehensive financial data presented. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2021-04-22 Chinese
安图生物2020年度控股股东及其他关联方资金占用情况专项说明
Regulatory Filings
2021-04-22 Chinese
安图生物2020年度内部控制审计报告
Regulatory Filings
2021-04-22 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.